Operationalizing Subcutaneous Checkpoint Inhibitors in Practice. Implementing subcutaneous checkpoint inhibitors requires ...

The first under-the-skin, long-acting risperidone injection offers a new maintenance option for adults with bipolar 1 ...

GSK’s ViiV Healthcare and its bimonthly pre-exposure prophylaxis (PrEP) medicine Apretude had to make room for another long-acting PrEP option this summer, when rival Gilead Sciences rolled out Yez | ...

Halozyme Therapeutics has been busy. While fighting a patent dispute with Merck & Co. | Halozyme scoured very broadly for ...

Viehbacher, “Biogen”) announced today that LEQEMBI ® IQLIK™, a subcutaneous autoinjector formulation of lecanemab (generic name), for the treatment of Alzheimer’s disease (AD) has been selected by ...

The U.S. Food and Drug Administration recently approved Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) for ...

"For many patients, having a subcutaneous induction option is an important step forward—offering the flexibility of at-home administration after proper training without compromising efficacy," said ...

New LEQEMBI Companion TM program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide patients with injection training, and an ...

New LEQEMBI Companion™ program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who ...

Eisai Co. (ESAIY) and Biogen (BIIB) announced that lecanemab-irmb subcutaneous injection, U.S. brand name: LEQEMBI IQLIKTM, ...